NasdaqGS - Delayed Quote USD
Grifols, S.A. (GRFS)
8.10 +0.06 (+0.75%)
At close: October 30 at 4:00:01 PM EDT
Trade GRFS on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for GRFS
- Previous Close
8.04 - Open
8.10 - Bid 6.95 x 100
- Ask 9.28 x 100
- Day's Range
8.05 - 8.25 - 52 Week Range
6.96 - 9.90 - Volume
803,382 - Avg. Volume
535,734 - Market Cap (intraday)
5.513B - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
10.52 - EPS (TTM)
0.77 - Earnings Date --
- Forward Dividend & Yield 0.11 (1.31%)
- 1y Target Est
10.36 - Zacks Rating Neutral
Recent News
View More
Performance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is IBEX 35 (^IBEX) .
YTD Return
GRFS
10.77%
IBEX 35 (^IBEX)
7.48%
1-Year Return
GRFS
12.58%
IBEX 35 (^IBEX)
15.50%
3-Year Return
GRFS
6.44%
IBEX 35 (^IBEX)
109.15%
5-Year Return
GRFS
36.34%
IBEX 35 (^IBEX)
105.93%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 10/30/2026
Market Cap
7.31B
Enterprise Value
19.21B
Trailing P/E
10.52
Forward P/E
6.72
PEG Ratio (current)
0.35
Price/Sales (ttm)
0.64
Price/Book (mrq)
0.87
Enterprise Value/Revenue
2.22
Enterprise Value/EBITDA
10.70
Financial Highlights
Profitability and Income Statement
Profit Margin
6.09%
Return on Assets (ttm)
4.23%
Return on Equity (ttm)
6.93%
Revenue (ttm)
7.42B
Net Income Avi to Common (ttm)
452M
Diluted EPS (ttm)
0.77
Balance Sheet and Cash Flow
Total Cash (mrq)
537M
Total Debt/Equity (mrq)
117.24%
Levered Free Cash Flow (ttm)
572.92M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreGrifols: Dropping Coverage
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Grifols: Maintaining Our Fair Value Estimate as Board Does Not Support Potential Offer Price
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Grifols Earnings: Strong Third Quarter as Potential Private Equity Deal Still in Progress
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Grifols Earnings: Leverage and Cash Flow Improve as Discussions Continue on Going Private
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.